论文部分内容阅读
目的分析莫西沙星及左氧氟沙星治疗耐多药肺结核的临床效果比较。方法选取耐多药肺结核患者68例,按照抛硬币法分为观察组35例和对照组33例,在常规治疗基础上,观察组联合莫西沙星治疗,对照组联合左氧氟沙星治疗,比较2组患者治疗后3个月、6个月及12个月的痰菌转阴情况、空洞改善情况。结果治疗后3、6个月时2组痰菌阴转率比较差异无统计学意义(P>0.05);治疗后12个月时观察组痰菌阴转率高于对照组,差异有统计学意义(P<0.05)。观察组空洞改善总有效率为94.3%,高于对照组的75.8%,差异有统计学意义(χ~2=4.649,P<0.05)。结论在耐多药肺结核治疗中,莫西沙星治疗效果优于左氧氟沙星治疗,可有效改善空洞情况,提高痰菌阴转率。
Objective To compare the clinical effects of moxifloxacin and levofloxacin in the treatment of multidrug-resistant pulmonary tuberculosis. Methods Sixty-eight patients with MDR-TB were selected and divided into observation group (n = 35) and control group (n = 33) according to the coin-tossing method. On the basis of routine treatment, the observation group was treated with moxifloxacin and the control group was treated with levofloxacin. After 3 months, 6 months and 12 months of sputum negative conversion, empty improvement. Results There was no significant difference in sputum negative conversion rate between the two groups at 3 and 6 months after treatment (P> 0.05). At 12 months after treatment, sputum negative conversion rate in the observation group was higher than that in the control group Significance (P <0.05). The total effective rate of cavity improvement in the observation group was 94.3%, which was higher than that in the control group (75.8%), the difference was statistically significant (χ ~ 2 = 4.649, P <0.05). Conclusion Moxifloxacin is superior to levofloxacin in MDR-TB treatment, which can effectively improve the cavity and improve the sputum negative conversion rate.